REGENERON Aktie

>REGENERON Aktienkurs

636.2 EUR -2.9% (TradegateBSX)

Ask: 641.8 EUR / 100 Stück

Bid: 640.7 EUR / 100 Stück

Tagesumsatz: 120 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENERON Aktie über LYNX handeln

Intraday

1 Jahr

>REGENERON Performance

1 Woche: +0,6%

1 Monat: -0,5%

3 Monate: -0,3%

6 Monate: +27,5%

1 Jahr: +21,4%

laufendes Jahr: -4,1%

>REGENERON Aktie

Name:

REGENERON PHARMAC.DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US75886F1075 / 881535

Symbol/ Ticker:

RGO (Frankfurt) / REGN (NASDAQ)

Kürzel:

FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN

Index:

S&P500, Nasdaq100

Webseite:

http://www.regeneron.com/

Profil:

Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship products including Eylea and Eylea HD for eye dis..
>Volltext..

Marktkapitalisierung:

69078.78 Mio. EUR

Unternehmenswert:

64293.86 Mio. EUR

Umsatz:

12236.46 Mio. EUR

EBITDA:

3622.16 Mio. EUR

Nettogewinn:

3843.3 Mio. EUR

Gewinn je Aktie:

36.79 EUR

Schulden:

2536.12 Mio. EUR

Liquide Mittel:

2664.94 Mio. EUR

Operativer Cashflow:

4247.68 Mio. EUR

Bargeldquote:

1.97

Umsatzwachstum:

-10.98%

Gewinnwachstum:

-10.02%

Dividende je Aktie:

3.19 EUR

Dividendenrendite:

0.47%

Dividendenschätzung:

0.51%

Div. Historie:

20.02.26 - 0.798906€
20.11.25 - 0.76287204€

>weitere anzeigen...

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 77.727 USD.

Suchwörter:

REGENERON

Letzte Datenerhebung:

26.04.26

>REGENERON Kennzahlen

Aktien/ Unternehmen:

Aktien: 103.9 Mio. St.

Frei handelbar: 97.94%

Leerverk. Aktien: 2.74%

Rückkaufquote: 3.46%

Mitarbeiter: 15410

Umsatz/Mitarb.: 0.79 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 16.36%

Bewertung:

KGV: 18.42

KGV lG: 16.71

KUV: 5.58

KBV: 2.59

PEG-Ratio: 2.09

EV/EBITDA: 17.75

Rentabilität:

Bruttomarge: 81.56%

Gewinnmarge: 31.41%

Operative Marge: 25.81%

Managementeffizenz:

Gesamtkaprendite: 11.49%

Eigenkaprendite: 14.87%

>REGENERON Peer Group

Gesundheit, Augenmedizin, Lungenerkrankungen & -behandlung/ Asthma, Hauterkrankungen & -behandlung/ Dermatologie, Onkologie/ Krebs- Behandlung
>Alle Branchen..

>REGENERON Chart & Kurs - NASDAQ

>REGENERON News

24.04.26 - 21:18	Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss (CNBC)
	Regeneron will make its newly approved gene therapy available for free in the U.S. The company hasn't yet decided how much it will charge in other countries....

24.04.26 - 20:45

FDA Approves First Gene Therapy To Treat Deafness (ZeroHedge)

FDA Approves First Gene Therapy To Treat Deafness Authored by Zachary Stieber via The Epoch Times (emphasis ours), Federal regulators on Thursday approved the first gene therapy to restore hearing, just two months after the therapy's maker formally requested a license. Dr. Marty Makary, the Food and Drug Administration's commissioner, in an undated file photograph. Madalina Vasiliu/The Epoch Times The Food and Drug Administration approved the Regeneron therapy, Otarmeni, for children and adults with severe or profound hearing loss associated with OTOF gene variants. The approval came 61 days after Regeneron filed for a biologics license, under a new effort known as the Commissioner's National Priority Voucher Program that emphasizes quickly reviewing applications for products that address unmet needs. “Today's approval is a significant milestone in the treatment of genetic hearing loss,” Dr. Marty Makary, the FDA's commissioner, said in a statement. “Through the national priority vo...

24.04.26 - 18:36	Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It′s A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia (AFX)
	NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multi......

24.04.26 - 16:45	Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
	Get a deeper insight into the potential performance of Regeneron (REGN) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics....

24.04.26 - 13:12	Regeneron Agrees To Lower Prescription Drug Prices Under MFN Deal (AFX)
	WASHINGTON (dpa-AFX) - President Donald Trump has announced an MFN pricing deal with Regeneron to lower prescription drug prices that Americans pay for some of the world's most innovative drugs, i......

24.04.26 - 06:30	Regeneron Pharma: FDA Grants Approval For Otarmeni, Gene Therapy For Genetic Hearing Loss (AFX)
	LONDON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the FDA has granted accelerated approval for Otarmeni, the first gene therapy and second new molecular entity approved under the FDA C......

23.04.26 - 21:48	Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. (GlobeNewswire EN)
	Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S....

23.04.26 - 21:42	Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free (CNBC)
	Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump....

23.04.26 - 19:48	FDA Approves First-Ever Gene Therapy to Restore Hearing (WSJ EN)
	Regeneron's drug restored hearing in 11 of 12 children in a rare, inherited condition that causes deafness....

23.04.26 - 19:30	White House to announce drug pricing deal with Regeneron (Reuters EN)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

23.04.26 - 19:21	Regeneron wins FDA approval for hearing loss therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.04.26 - 19:12	Trump will unveil a deal with Regeneron to lower drug prices (AP)
	Um den gesamten Artikel unter apnews.com zu lesen, klicken Sie bitte auf die Überschrift...

23.04.26 - 18:42	Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. (GlobeNewswire EN)
	Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers...

23.04.26 - 18:18	Regeneron is said to have reached a drug pricing deal with U.S. (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.04.26 - 18:01	Regeneron Agrees to Lower Drug Prices, Gets Gene Therapy Nod (Bloomberg)
	Regeneron Pharmaceuticals Inc. reached a deal with the Trump administration to lower drug costs for some Americans and won US approval for its gene therapy to treat a rare form of deafness, according to a person who declined to be identified in order to speak before the announcement was made....

22.04.26 - 23:33	Press Release: Sanofi and Regeneron′s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria (GlobeNewswire EN)
	Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria...

22.04.26 - 17:30	Regeneron (REGN) Earnings Expected to Grow: Should You Buy? (Zacks)
	Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

21.04.26 - 20:18	Regeneron Reports Positive Phase 3 Data For Cemdisiran In Myasthenia Gravis (AFX)
	WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) reported positive Phase 3 results for cemdisiran in Generalized Myasthenia Gravis, with the NIMBLE trial meeting primary and key secondary e......

20.04.26 - 22:09	Regeneron Announces Investor Conference Presentations (GlobeNewswire EN)
	TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:...

17.04.26 - 17:24

XETR: Deletion of Instruments from XETRA - 17.04.2026 -2- (XETRA)

The following instruments on XETRA do have their last trading day on 17.04.2026. Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026. ISIN Name US5719032022 Marriott International Inc. US57667L1070 Match Group Inc. US59156R1086 MetLife Inc. US5926881054 Mettler-Toledo International Inc. US5950171042 Microchip Technology Inc. US6200763075 Motorola Solutions Inc. US64110D1046 NetApp Inc. US6293775085 NRG Energy Inc. NL0009538784 NXP Semiconductors NV US6819191064 Omnicom Group Inc. US68902V1070 Otis Worldwide Corp. US6937181088 PACCAR Inc. US7043261079 Paychex Inc. US69331C1080 PG & E Corp. US7185461040 Phillips 66 US69351T1060 PPL Corp. US69370C1009 PTC Inc. GB00BY2Z0H74 Puretech Health PLC US7512121010 Ralph Lauren Corp. US75886F1075 Regeneron Pharmaceuticals Inc. US74967X1037 RH US7739031091 Rockwell Automation Inc. DK0063855168 Rockwool A/S US77543R1023 Roku Inc. US7782961038 Ross Stores Inc. US8168511090 Sempra US83088M1027 Skyworks Solutions...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: So wertlos ist keiner, daß er nicht wenigstens als schlechtes Beispiel herhalten könnte. - Markus M. Ronner

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram